Gregory W. Roloff, MD, on Confirming Durable Efficacy of Brexu-Cel and Maintenance Therapy in B-ALL
The chief hematology/oncology fellow at University of Chicago discussed real-world experience data and new analyses of patients with B-cell acute lymphoblastic leukemia treated with brexu-cel.
“The main question that we really wanted to answer after we established that these remissions were durable, was, how do we keep them there? And how do we maintain a disease-free state? So, we performed uni- and multivariate analysis to see, and, ultimately, confirm, that the use of consolidation and maintenance therapies... signaled for superior progression free survival."
Real-world, clinical use of brexucabtagene autoleucel (Tecartus; Kite) in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) has demonstrated a 90% complete response rate and 82% minimal residual disease negativity rate. These data, across sites in the United States, are from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) study presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California, by Gregory Roloff, MD, chief hematology/oncology fellow, University of Chicago.
Investigators, including Roloff, also observed a benefit in progression-free survival in patients that also received maintenance or consolidation therapy, In terms of safety, there were low rates of severe cytokine release syndrome but a 32% rate of grade 3-4 immune effector cell-associated neurotoxicity syndrome.
CGTLive spoke with Roloff to learn more about the new real-world data presented. He also discussed the positive outcomes observed with patients with central nervous system involvement of their leukemia and leukemic infiltration of the spinal canal, a population that was excluded from the pivotal ZUMA-3 trial (NCT02614066).
Click here to view more coverage of the 2023 ASH meeting.
